董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rostislav Raykov | 男 | Chief Executive Officer, Director | 48 | 212.42万美元 | 未持股 | 2021-05-25 |
| Adrian J. Haigh | 男 | Director | 65 | 16.03万美元 | 未持股 | 2021-05-25 |
| Shubh Goel | 女 | Director | 50 | 52.94万美元 | 未持股 | 2021-05-25 |
| Jodi Cook | 女 | Director | 56 | 19.53万美元 | 未持股 | 2021-05-25 |
| Khalid Islam | 男 | Chairman of Board, Director | 69 | 23.54万美元 | 未持股 | 2021-05-25 |
| Marco Brughera | 男 | Director | 68 | 16.03万美元 | 未持股 | 2021-05-25 |
| Chris A. Rallis | 男 | Director | 71 | 16.28万美元 | 未持股 | 2021-05-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert Andrade | 男 | Chief Financial Officer | 49 | 115.89万美元 | 未持股 | 2021-05-25 |
| Rostislav Raykov | 男 | Chief Executive Officer, Director | 48 | 212.42万美元 | 未持股 | 2021-05-25 |
董事简历
中英对照 | 中文 | 英文- Rostislav Raykov
-
Rostislav Raykov自2009年7月以来担任FENNEC的董事，自2009年7月以来担任首席执行官。Raykov从2006年1月到2007年12月担任Alchem Investment Partners and John Levin&Co.投资组合经理。在创立Alchem之前，Raykov先生是John A.Levin&Co.的投资组合经理和证券分析师。2002-2005年活动驱动基金。在加入John A.Levin&Co.之前，Raykov先生是Tiedemann Investment Group合并基金的证券分析师（1999-2002）和Bear Stearns的投资银行分析师（1998-1999）。Raykov先生在北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）获得工商管理学士学位。由于这些和其他专业经验，随着公司在药物开发行业的发展，Raykov先生在公司拥有财务专业知识和经验，因此能够为我们提供独特的见解和指导。
Rostislav Raykov has served as a director and as Chief Executive Officer of Fennec since July 2009. From January 2006 to December 2007 Mr. Raykov was a portfolio manager for Alchem Investment Partners. Prior to founding Alchem, Mr. Raykov was a portfolio manager and securities analyst for John A. Levin & Co. Event Driven Fund 2002-2005. Prior to joining John A. Levin & Co., Mr. Raykov was a securities analyst for the Merger Fund at Tiedemann Investment Group (1999-2002) and an investment banking analyst at Bear Stearns (1998-1999). Mr. Raykov earned a B.S. in Business Administration from the University of North Carolina at Chapel Hill. - Rostislav Raykov自2009年7月以来担任FENNEC的董事，自2009年7月以来担任首席执行官。Raykov从2006年1月到2007年12月担任Alchem Investment Partners and John Levin&Co.投资组合经理。在创立Alchem之前，Raykov先生是John A.Levin&Co.的投资组合经理和证券分析师。2002-2005年活动驱动基金。在加入John A.Levin&Co.之前，Raykov先生是Tiedemann Investment Group合并基金的证券分析师（1999-2002）和Bear Stearns的投资银行分析师（1998-1999）。Raykov先生在北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）获得工商管理学士学位。由于这些和其他专业经验，随着公司在药物开发行业的发展，Raykov先生在公司拥有财务专业知识和经验，因此能够为我们提供独特的见解和指导。
- Rostislav Raykov has served as a director and as Chief Executive Officer of Fennec since July 2009. From January 2006 to December 2007 Mr. Raykov was a portfolio manager for Alchem Investment Partners. Prior to founding Alchem, Mr. Raykov was a portfolio manager and securities analyst for John A. Levin & Co. Event Driven Fund 2002-2005. Prior to joining John A. Levin & Co., Mr. Raykov was a securities analyst for the Merger Fund at Tiedemann Investment Group (1999-2002) and an investment banking analyst at Bear Stearns (1998-1999). Mr. Raykov earned a B.S. in Business Administration from the University of North Carolina at Chapel Hill.
- Adrian J. Haigh
-
AdrianJ.Haigh自2014年9月起担任PtcTherapeutics，Inc.欧洲、中东和非洲地区及亚太区高级副总裁兼总经理。此前，Haigh先生自2011年3月起担任Gentium GmbH的高级副总裁，商业运营和首席运营官。在加入Gentium公司之前，Haigh先生曾担任Biogen Idec公司的区域Vice President和商业运营经理，他在该公司管理几家附属公司以及全球经销商业务，在此之前，他曾担任Amgen Nordis公司和葡萄牙公司的总经理。他曾担任EUSA Pharma公司的负责全球营销和企业规划的执行Vice President，并从Amgen公司加入EUSA公司，在那里他曾领导国际肿瘤专营权。Haigh先生此前曾在SmithKline Beecham，Schering Plough，Organon和Novo Nordisk担任高级商业和营销职位。他自2014年4月28日起担任Fennec PharmaceuticalsInc.董事，自2014年8月21日起担任Arch Biopartners Inc.董事。他在英国西约克郡哈德斯菲尔德理工学院（Huddersfield Polytechnic）以优异成绩获得经济史文学学士学位，并在市场营销学院（Institute of Marketing）获得市场营销文凭。由于这些和其他专业经验，Haigh先生拥有广泛的国际肿瘤学发展专业知识，这加强了董事会的集体资格，技能和经验。
Adrian J. Haigh has been a director of Fennec since April 2014. Mr. Haigh has been Senior Vice President and Head of International Operations at PTC Therapeutics since September 2014. Previously Mr. Haigh served as Chief Operating Officer at Gentium GmbH from 2011 until 2014. Prior to joining Gentium, Mr. Haigh served as Regional VP Commercial Operations at Biogen Idec where he managed several affiliates and also the global distributor business and prior to that was the General Manager of Amgen Nordis and Portugal. He served as the Executive Vice President of Global Marketing and Corporate Planning at EUSA Pharma and joined EUSA from Amgen where he led the international oncology franchise. Mr. Haigh previously has held senior commercial and marketing positions at SmithKline Beecham, Schering Plough, Organon and Novo Nordisk. He has been director at Arch Biopartners Inc. since August 21 2014. He received a Bachelor of Arts with Honors in Economic History from Huddersfield Polytechnic, West Yorkshire, England and a Diploma in Marketing from the Institute of Marketing. - AdrianJ.Haigh自2014年9月起担任PtcTherapeutics，Inc.欧洲、中东和非洲地区及亚太区高级副总裁兼总经理。此前，Haigh先生自2011年3月起担任Gentium GmbH的高级副总裁，商业运营和首席运营官。在加入Gentium公司之前，Haigh先生曾担任Biogen Idec公司的区域Vice President和商业运营经理，他在该公司管理几家附属公司以及全球经销商业务，在此之前，他曾担任Amgen Nordis公司和葡萄牙公司的总经理。他曾担任EUSA Pharma公司的负责全球营销和企业规划的执行Vice President，并从Amgen公司加入EUSA公司，在那里他曾领导国际肿瘤专营权。Haigh先生此前曾在SmithKline Beecham，Schering Plough，Organon和Novo Nordisk担任高级商业和营销职位。他自2014年4月28日起担任Fennec PharmaceuticalsInc.董事，自2014年8月21日起担任Arch Biopartners Inc.董事。他在英国西约克郡哈德斯菲尔德理工学院（Huddersfield Polytechnic）以优异成绩获得经济史文学学士学位，并在市场营销学院（Institute of Marketing）获得市场营销文凭。由于这些和其他专业经验，Haigh先生拥有广泛的国际肿瘤学发展专业知识，这加强了董事会的集体资格，技能和经验。
- Adrian J. Haigh has been a director of Fennec since April 2014. Mr. Haigh has been Senior Vice President and Head of International Operations at PTC Therapeutics since September 2014. Previously Mr. Haigh served as Chief Operating Officer at Gentium GmbH from 2011 until 2014. Prior to joining Gentium, Mr. Haigh served as Regional VP Commercial Operations at Biogen Idec where he managed several affiliates and also the global distributor business and prior to that was the General Manager of Amgen Nordis and Portugal. He served as the Executive Vice President of Global Marketing and Corporate Planning at EUSA Pharma and joined EUSA from Amgen where he led the international oncology franchise. Mr. Haigh previously has held senior commercial and marketing positions at SmithKline Beecham, Schering Plough, Organon and Novo Nordisk. He has been director at Arch Biopartners Inc. since August 21 2014. He received a Bachelor of Arts with Honors in Economic History from Huddersfield Polytechnic, West Yorkshire, England and a Diploma in Marketing from the Institute of Marketing.
- Shubh Goel
-
Shubh Goel自2019年9月起受雇于我们。根据日期为2019年9月9日的雇佣协议，Goel女士被聘为Fennec&8217；s首席商务官，并且:A获得了初始年薪$360000，可由我们的董事会进行年度调整，（b）由首席执行官和董事会酌情决定，可以每十二个月获得最多为其基本工资40%的年度奖金。如果Goel女士的雇用因原因以外的任何其他原因被我们终止，我们有义务向Goel女士支付（i）遣散费，金额为三个月的员工基本工资或如果终止合同发生在（a）她受雇两周年之后或（b）由于控制权变更而导致六个月的遣散费，（ii）Goel女士获得的任何目标奖金的按比例分配，并且，（iii）加速授予股票期权。该协议的初始期限为一年，除非任何一方根据该协议终止，否则该协议将自动延长一年。
Shubh Goel as been employed by us since September 2019. Ms. Goel is a proven leader with 20 years of global commercial experience successfully building and executing the launch of several oncology products. Most recently, she served as Vice President of Commercial Strategy and Operations at Odonate Therapeutics, Inc. Prior to Odonate, Ms. Goel previously served in multiple leadership positions at Celgene Corporation, including serving as Executive Director, Global Early Commercialization and previously as Head of U.S. Marketing, Oncology. While at Celgene, she oversaw the successful execution of the U.S. launch of Abraxane® in pancreatic cancer and had overall responsibility for marketing the U.S. solid tumor franchise. Ms. Goel received a B.Sc. degree in biochemistry from the University of Bath. - Shubh Goel自2019年9月起受雇于我们。根据日期为2019年9月9日的雇佣协议，Goel女士被聘为Fennec&8217；s首席商务官，并且:A获得了初始年薪$360000，可由我们的董事会进行年度调整，（b）由首席执行官和董事会酌情决定，可以每十二个月获得最多为其基本工资40%的年度奖金。如果Goel女士的雇用因原因以外的任何其他原因被我们终止，我们有义务向Goel女士支付（i）遣散费，金额为三个月的员工基本工资或如果终止合同发生在（a）她受雇两周年之后或（b）由于控制权变更而导致六个月的遣散费，（ii）Goel女士获得的任何目标奖金的按比例分配，并且，（iii）加速授予股票期权。该协议的初始期限为一年，除非任何一方根据该协议终止，否则该协议将自动延长一年。
- Shubh Goel as been employed by us since September 2019. Ms. Goel is a proven leader with 20 years of global commercial experience successfully building and executing the launch of several oncology products. Most recently, she served as Vice President of Commercial Strategy and Operations at Odonate Therapeutics, Inc. Prior to Odonate, Ms. Goel previously served in multiple leadership positions at Celgene Corporation, including serving as Executive Director, Global Early Commercialization and previously as Head of U.S. Marketing, Oncology. While at Celgene, she oversaw the successful execution of the U.S. launch of Abraxane® in pancreatic cancer and had overall responsibility for marketing the U.S. solid tumor franchise. Ms. Goel received a B.Sc. degree in biochemistry from the University of Bath.
- Jodi Cook
-
Jodi Cook目前担任PtcTherapeutics，Inc.基因治疗战略主管，该公司是一家全球生物制药公司，专注于为罕见疾病患者提供益处的临床差异化药物的开发和商业化。加入PTC Therapeutics公司之前，她曾担任Agilis Biotherapeutics公司（临床阶段公司，专注于罕见病患者的基因疗法）的创始成员之一兼首席运营官。重要的是，她的职业生涯涵盖与Fennec&8217；的商业利益相关的广泛经验，包括Mayo Clinic的听力学助理教授和助听器计划总监，以及听力行业内多个成功的生物技术初创企业的执行职位。任职Agilis公司期间，她曾领导将公司出售给PTC Therapeutics公司，这一交易对各方都具有重大价值。她丰富的科学、临床和执行业务经验加深了董事会的集体资格、技能和经验。
Jodi Cook has been a director of Fennec since September 2019. Dr. Cook previously served as SVP and Head of Gene Therapy Strategy at PTC Therapeutics from August 2018 until February 2020. Previously she was one of the founding members and Chief Operating Officer of Agilis Biotherapeutics, a clinical-stage company focused on gene therapies for rare diseases of the central nervous system, from December 2013 until its acquisition by PTC Therapeutics in August 2018. While at Agilis she led the sale of the company to PTC in a deal that represented significant value to all parties. Dr. Cook's career spans a wide range of experiences including VP of Clinical Research at InSound Medical and Director of Audiology at Songbird Hearing, both successful biotech start-up companies within the hearing industry. She has been Assistant Professor of Audiology and Director of the Hearing Aid Program at Mayo Clinic. Dr Cook earned a BA from Loyola University in Maryland, M.Aud. from University of South Carolina, and PhD from Arizona State University in Hearing Science. - Jodi Cook目前担任PtcTherapeutics，Inc.基因治疗战略主管，该公司是一家全球生物制药公司，专注于为罕见疾病患者提供益处的临床差异化药物的开发和商业化。加入PTC Therapeutics公司之前，她曾担任Agilis Biotherapeutics公司（临床阶段公司，专注于罕见病患者的基因疗法）的创始成员之一兼首席运营官。重要的是，她的职业生涯涵盖与Fennec&8217；的商业利益相关的广泛经验，包括Mayo Clinic的听力学助理教授和助听器计划总监，以及听力行业内多个成功的生物技术初创企业的执行职位。任职Agilis公司期间，她曾领导将公司出售给PTC Therapeutics公司，这一交易对各方都具有重大价值。她丰富的科学、临床和执行业务经验加深了董事会的集体资格、技能和经验。
- Jodi Cook has been a director of Fennec since September 2019. Dr. Cook previously served as SVP and Head of Gene Therapy Strategy at PTC Therapeutics from August 2018 until February 2020. Previously she was one of the founding members and Chief Operating Officer of Agilis Biotherapeutics, a clinical-stage company focused on gene therapies for rare diseases of the central nervous system, from December 2013 until its acquisition by PTC Therapeutics in August 2018. While at Agilis she led the sale of the company to PTC in a deal that represented significant value to all parties. Dr. Cook's career spans a wide range of experiences including VP of Clinical Research at InSound Medical and Director of Audiology at Songbird Hearing, both successful biotech start-up companies within the hearing industry. She has been Assistant Professor of Audiology and Director of the Hearing Aid Program at Mayo Clinic. Dr Cook earned a BA from Loyola University in Maryland, M.Aud. from University of South Carolina, and PhD from Arizona State University in Hearing Science.
- Khalid Islam
-
Khalid Islam，他曾一直担任我们的董事会主席（2009年12月以来），以及我们的首席执行官（2009年11月以来）。他在制药行业有着超过22年的经验。从1999年到2008年，他担任Arpida AG（瑞士证交所上市的抗感染公司）的总裁兼首席执行官。加入Arpida公司之前，他曾担任Hoechst Marion Roussel（全球制药公司）、Marion-Merrell Dow公司（全球制药公司）的多种研发职务。他是几家公司的创始人之一，此前曾担任Arpida AG（位于瑞士）、Rheoscience A / S（位于丹麦）的董事会成员，以及Arpida公司的主席。此外，他是C10 Pharma公司（位于挪威，巴黎风险资本集团Kurma Biofund公司的顾问）的董事会现任主席、the Network of Excellence in Pathogenomics的国际科学顾问委员会的成员，以及Current Drug Discovery and Technologies的编辑部成员。他持有伦敦大学切尔西学院（Chelsea College, University of London）的学士学位，以及伦敦帝国理工学院（Imperial College, University of London）的哲学博士学位。他在科学期刊上发表了超过80篇文章，拥有众多的专利。
Khalid Islam has been a director of Fennec since April 2014 and is our current Chairman of the Board. Dr. Islam was the Chairman and CEO of Gentium S.p.A. a Nasdaq-listed company; 2009-2014 where he led the transition from a loss-making to a cash-flow positive and profitable company. Under his leadership, the company value increased from US$25 million leading to a successful all cash US$1 billion merger with Jazz Pharmaceuticals, plc. Subsequent to the sale of Gentium, Dr. Islam has been involved from both an advisory and board level in several public and private healthcare related companies. From 1999-2008 Dr. Islam was President and CEO of Arpida AG where he transitioned the early-stage start-up to a SWX-listed company and raised US$300 million in the IPO and follow-ons. From 1987-1999 he held various positions in HMR & MMD (now Sanofi-Aventis). From 1977-1987 Dr. Islam worked in academia at Imperial College (Univ. of London) and in Milan University, where he was a contract professor. Dr. Islam is a graduate of Chelsea College and received his Ph.D. from Imperial College, University of London. He holds several patents and has published over 80 articles in leading journals. He is an advisor to the venture group Kurma Biofund (Paris). He is a founder/co-founder of Sirius Healthcare Partners GmbH (Zurich), PrevAbr LLC (D.C.), BioAim LLC (L.A.) & Life Sciences Management GmbH (Zug). Dr. Islam is Board Chair at Minoryx Therapeutics (Spain) and Gain Therapeutics (Switzerland), a public company. He currently serves on the board of Gain Therapeutics (GAIN) and Processa Pharmaceuticals (PCSA), both of which are publicly traded. In the past, he has served as Chairman of the Board of Directors of Immunomedics (USA), Pcovery Aps (Copenhagen), Adenium Aps (Copenhagen) and C10 Pharma AS (Oslo) and on the board of Karolinska Development (Sweden) and MolMed S.p.A. (Italy). - Khalid Islam，他曾一直担任我们的董事会主席（2009年12月以来），以及我们的首席执行官（2009年11月以来）。他在制药行业有着超过22年的经验。从1999年到2008年，他担任Arpida AG（瑞士证交所上市的抗感染公司）的总裁兼首席执行官。加入Arpida公司之前，他曾担任Hoechst Marion Roussel（全球制药公司）、Marion-Merrell Dow公司（全球制药公司）的多种研发职务。他是几家公司的创始人之一，此前曾担任Arpida AG（位于瑞士）、Rheoscience A / S（位于丹麦）的董事会成员，以及Arpida公司的主席。此外，他是C10 Pharma公司（位于挪威，巴黎风险资本集团Kurma Biofund公司的顾问）的董事会现任主席、the Network of Excellence in Pathogenomics的国际科学顾问委员会的成员，以及Current Drug Discovery and Technologies的编辑部成员。他持有伦敦大学切尔西学院（Chelsea College, University of London）的学士学位，以及伦敦帝国理工学院（Imperial College, University of London）的哲学博士学位。他在科学期刊上发表了超过80篇文章，拥有众多的专利。
- Khalid Islam has been a director of Fennec since April 2014 and is our current Chairman of the Board. Dr. Islam was the Chairman and CEO of Gentium S.p.A. a Nasdaq-listed company; 2009-2014 where he led the transition from a loss-making to a cash-flow positive and profitable company. Under his leadership, the company value increased from US$25 million leading to a successful all cash US$1 billion merger with Jazz Pharmaceuticals, plc. Subsequent to the sale of Gentium, Dr. Islam has been involved from both an advisory and board level in several public and private healthcare related companies. From 1999-2008 Dr. Islam was President and CEO of Arpida AG where he transitioned the early-stage start-up to a SWX-listed company and raised US$300 million in the IPO and follow-ons. From 1987-1999 he held various positions in HMR & MMD (now Sanofi-Aventis). From 1977-1987 Dr. Islam worked in academia at Imperial College (Univ. of London) and in Milan University, where he was a contract professor. Dr. Islam is a graduate of Chelsea College and received his Ph.D. from Imperial College, University of London. He holds several patents and has published over 80 articles in leading journals. He is an advisor to the venture group Kurma Biofund (Paris). He is a founder/co-founder of Sirius Healthcare Partners GmbH (Zurich), PrevAbr LLC (D.C.), BioAim LLC (L.A.) & Life Sciences Management GmbH (Zug). Dr. Islam is Board Chair at Minoryx Therapeutics (Spain) and Gain Therapeutics (Switzerland), a public company. He currently serves on the board of Gain Therapeutics (GAIN) and Processa Pharmaceuticals (PCSA), both of which are publicly traded. In the past, he has served as Chairman of the Board of Directors of Immunomedics (USA), Pcovery Aps (Copenhagen), Adenium Aps (Copenhagen) and C10 Pharma AS (Oslo) and on the board of Karolinska Development (Sweden) and MolMed S.p.A. (Italy).
- Marco Brughera
-
Marco Brughera一直担任Lediant Biosciences SpA的首席执行官，并曾担任Sigma-Tau集团的多个职位，包括Sigma Tau罕见病首席执行官兼全球主管、Sigma-Tau研究总裁和Sigma-Tau制药公司总裁。他推动了Lead Oncology产品线的商业复兴，导致其以总计约9亿美元的价格成功销售。他还成功地将DeFibrotide US的权利授权给Jazz Pharmaceuticals。从2004年到2010年，Brughera博士担任Nerviano Medical Sciences NMS的临床前开发Vice President，该公司是一家专注于药物肿瘤学的综合发现和开发公司。他也曾担任Accelera公司（NMS Group的独立合同研究组织）的董事总经理。从1999年到2004年，Brughera博士在Pharmacia和Pfizer的研究与开发领域担任过多个高级职位。1999年之前，他曾担任Pharmacia&Upjohn公司和Farmitalia Carlo Erba SpA公司（意大利制药公司）的多种职务。他目前任职于Solgenix and Lee&8217；s Pharmaceutical的董事会，直到2014年初，他曾担任Gentium SpA的董事会成员。Brughera博士在米兰大学（University of Milan）获得兽医学学位，是一名欧洲注册毒理学家，Brughera先生在国际公司拥有广泛的药物开发经验和知识。特别是他在欧洲临床药物开发方面的知识，加深了董事会的集体资格、技能和经验。
Marco Brughera has been a director of Fennec since August 2016. Since January 2011 Dr. Brughera has been CEO of Lediant Biosciences SpA and has held several positions for the Sigma-Tau Group, including CEO and Global Head of Sigma Tau Rare Disease, President of Sigma-Tau Research and President of Sigma-Tau Pharmaceuticals. He drove the commercial revival of a lead oncology product line resulting in its successful sale for a total of around $900M. He also successfully out-licensed the Defibrotide US rights to Jazz Pharmaceuticals. From 2004 to 2010 Dr. Brughera served as the Vice President of Preclinical Development at Nerviano Medical Sciences NMS, a pharmaceutical oncology-focused integrated discovery and development company. He also served as the Managing Director at Accelera, an independent contract research organization with the NMS Group. From 1999 to 2004 Dr. Brughera held several senior level positions in the areas of research and development with Pharmacia and Pfizer. Prior to 1999 he held various positions at Pharmacia & Upjohn and Farmitalia Carlo Erba SpA, an Italian pharmaceutical company. He currently serves on the Board of Exelead and Naicons and previously was Board member of Soligenix, Lee's Pharmaceuticals and Gentium. - Marco Brughera一直担任Lediant Biosciences SpA的首席执行官，并曾担任Sigma-Tau集团的多个职位，包括Sigma Tau罕见病首席执行官兼全球主管、Sigma-Tau研究总裁和Sigma-Tau制药公司总裁。他推动了Lead Oncology产品线的商业复兴，导致其以总计约9亿美元的价格成功销售。他还成功地将DeFibrotide US的权利授权给Jazz Pharmaceuticals。从2004年到2010年，Brughera博士担任Nerviano Medical Sciences NMS的临床前开发Vice President，该公司是一家专注于药物肿瘤学的综合发现和开发公司。他也曾担任Accelera公司（NMS Group的独立合同研究组织）的董事总经理。从1999年到2004年，Brughera博士在Pharmacia和Pfizer的研究与开发领域担任过多个高级职位。1999年之前，他曾担任Pharmacia&Upjohn公司和Farmitalia Carlo Erba SpA公司（意大利制药公司）的多种职务。他目前任职于Solgenix and Lee&8217；s Pharmaceutical的董事会，直到2014年初，他曾担任Gentium SpA的董事会成员。Brughera博士在米兰大学（University of Milan）获得兽医学学位，是一名欧洲注册毒理学家，Brughera先生在国际公司拥有广泛的药物开发经验和知识。特别是他在欧洲临床药物开发方面的知识，加深了董事会的集体资格、技能和经验。
- Marco Brughera has been a director of Fennec since August 2016. Since January 2011 Dr. Brughera has been CEO of Lediant Biosciences SpA and has held several positions for the Sigma-Tau Group, including CEO and Global Head of Sigma Tau Rare Disease, President of Sigma-Tau Research and President of Sigma-Tau Pharmaceuticals. He drove the commercial revival of a lead oncology product line resulting in its successful sale for a total of around $900M. He also successfully out-licensed the Defibrotide US rights to Jazz Pharmaceuticals. From 2004 to 2010 Dr. Brughera served as the Vice President of Preclinical Development at Nerviano Medical Sciences NMS, a pharmaceutical oncology-focused integrated discovery and development company. He also served as the Managing Director at Accelera, an independent contract research organization with the NMS Group. From 1999 to 2004 Dr. Brughera held several senior level positions in the areas of research and development with Pharmacia and Pfizer. Prior to 1999 he held various positions at Pharmacia & Upjohn and Farmitalia Carlo Erba SpA, an Italian pharmaceutical company. He currently serves on the Board of Exelead and Naicons and previously was Board member of Soligenix, Lee's Pharmaceuticals and Gentium.
- Chris A. Rallis
-
Chris A. Rallis于2011年 12月担任董事。Mr. Rallis是Pappas Ventures（一家北卡罗来纳州达勒姆的生命科学合资公司）的驻地高管。2006年4月至2007年6月，他是ImmunoBiosciences, Inc.（一家位于北卡罗来纳州罗利的疫苗科技公司）的总裁和首席执行官。他在Duke University 和 Panacos Pharmaceuticals, Inc.担任过顾问，也是Triangle Pharmaceuticals, Inc.“Triangle”的前总裁和首席运营官，该公司于2003年1月被Gilead Sciences以将近4.65亿美元收购。在Triangle，他参与了11次股权融资总收益大约为5亿美元。他也主要负责所有的业务开发活动，包括Abbott Laboratories的全球联盟和10种化合物的许可。之前，他在Burroughs Wellcome, Co担任各类业务开发和法律管理的职务。Mr. Rallis在Aeolus Pharmaceuticals和 Adherex Technologies董事会担任主席，也是审计委员会的主席。他在Harvard College获得经济学学士学位，在Duke University获得法学博士。Mr. Rallis是审计委员会的成员。
Chris A. Rallis has served as a director of Fennec since August 2011. Mr. Rallis has been an executive-in-residence at Pappas Capital, a life science venture capital firm since January 2008. Previously, Mr. Rallis was the President and Chief Executive Officer of ImmunoBiosciences, Inc. "IBI", a vaccine technology company formerly located in Raleigh, North Carolina from April 2006 through June 2007. Prior to joining IBI, Mr. Rallis served as an executive in residence (part-time) for Pappas Capital, and as a consultant for Duke University and Panacos Pharmaceuticals, Inc. Mr. Rallis is the former President and Chief Operating Officer ("COO") and director of Triangle Pharmaceuticals, Inc., which was acquired by Gilead Sciences in January 2003 for approximately $465 million. Prior to assuming the role of President and COO in March 2000 he was Executive Vice President, Business Development and General Counsel. While at Triangle, Mr. Rallis participated in 11 equity financings generating gross proceeds of approximately $500 million. He was also primarily responsible for all business development activities which included a worldwide alliance with Abbott Laboratories and the in-licensing of ten compounds. Before joining Triangle in 1995 Mr. Rallis served in various business development and legal management roles with Burroughs Wellcome Co. over a 13-year period, including Vice President of Strategic Planning and Business Development. Mr. Rallis also serves on the board of Tenax Therapeutics, Inc., a biopharmaceutical company located in Morrisville, North Carolina. Mr. Rallis' term on the Tenax board expires on June 10 2021 and he is not standing for re-election. Mr. Rallis received his A.B. degree in economics from Harvard College and a J.D. from Duke University. - Chris A. Rallis于2011年 12月担任董事。Mr. Rallis是Pappas Ventures（一家北卡罗来纳州达勒姆的生命科学合资公司）的驻地高管。2006年4月至2007年6月，他是ImmunoBiosciences, Inc.（一家位于北卡罗来纳州罗利的疫苗科技公司）的总裁和首席执行官。他在Duke University 和 Panacos Pharmaceuticals, Inc.担任过顾问，也是Triangle Pharmaceuticals, Inc.“Triangle”的前总裁和首席运营官，该公司于2003年1月被Gilead Sciences以将近4.65亿美元收购。在Triangle，他参与了11次股权融资总收益大约为5亿美元。他也主要负责所有的业务开发活动，包括Abbott Laboratories的全球联盟和10种化合物的许可。之前，他在Burroughs Wellcome, Co担任各类业务开发和法律管理的职务。Mr. Rallis在Aeolus Pharmaceuticals和 Adherex Technologies董事会担任主席，也是审计委员会的主席。他在Harvard College获得经济学学士学位，在Duke University获得法学博士。Mr. Rallis是审计委员会的成员。
- Chris A. Rallis has served as a director of Fennec since August 2011. Mr. Rallis has been an executive-in-residence at Pappas Capital, a life science venture capital firm since January 2008. Previously, Mr. Rallis was the President and Chief Executive Officer of ImmunoBiosciences, Inc. "IBI", a vaccine technology company formerly located in Raleigh, North Carolina from April 2006 through June 2007. Prior to joining IBI, Mr. Rallis served as an executive in residence (part-time) for Pappas Capital, and as a consultant for Duke University and Panacos Pharmaceuticals, Inc. Mr. Rallis is the former President and Chief Operating Officer ("COO") and director of Triangle Pharmaceuticals, Inc., which was acquired by Gilead Sciences in January 2003 for approximately $465 million. Prior to assuming the role of President and COO in March 2000 he was Executive Vice President, Business Development and General Counsel. While at Triangle, Mr. Rallis participated in 11 equity financings generating gross proceeds of approximately $500 million. He was also primarily responsible for all business development activities which included a worldwide alliance with Abbott Laboratories and the in-licensing of ten compounds. Before joining Triangle in 1995 Mr. Rallis served in various business development and legal management roles with Burroughs Wellcome Co. over a 13-year period, including Vice President of Strategic Planning and Business Development. Mr. Rallis also serves on the board of Tenax Therapeutics, Inc., a biopharmaceutical company located in Morrisville, North Carolina. Mr. Rallis' term on the Tenax board expires on June 10 2021 and he is not standing for re-election. Mr. Rallis received his A.B. degree in economics from Harvard College and a J.D. from Duke University.
高管简历
中英对照 | 中文 | 英文- Robert Andrade
Robert Andrade自2015年11月起担任首席财务官。Andrade先生曾于2009年9月至2013年8月担任FENNEC的首席财务官和董事。除了他在Fennec的角色外，Andrade先生还是Magnetar Capital的高级分析师，Millennium Partners的投资组合经理和Caxton Associates的高级分析师。Andrade先生毕业于南加州大学（University of Southern California），在那里他获得文学硕士学位和经济学文学学士学位。
Robert Andrade has served as Chief Financial Officer since November 2015. Mr. Andrade was previously Chief Financial Officer and Director of Fennec from September 2009 until August 2013. In addition to his role with Fennec, Mr. Andrade was a private investor in 2015 and a senior analyst at Magnetar Capital from 2013 - 2014. Mr. Andrade graduated from University of Southern California, where he earned a Masters of Arts degree and Bachelor of Arts degree in economics.- Robert Andrade自2015年11月起担任首席财务官。Andrade先生曾于2009年9月至2013年8月担任FENNEC的首席财务官和董事。除了他在Fennec的角色外，Andrade先生还是Magnetar Capital的高级分析师，Millennium Partners的投资组合经理和Caxton Associates的高级分析师。Andrade先生毕业于南加州大学（University of Southern California），在那里他获得文学硕士学位和经济学文学学士学位。
- Robert Andrade has served as Chief Financial Officer since November 2015. Mr. Andrade was previously Chief Financial Officer and Director of Fennec from September 2009 until August 2013. In addition to his role with Fennec, Mr. Andrade was a private investor in 2015 and a senior analyst at Magnetar Capital from 2013 - 2014. Mr. Andrade graduated from University of Southern California, where he earned a Masters of Arts degree and Bachelor of Arts degree in economics.
- Rostislav Raykov
Rostislav Raykov自2009年7月以来担任FENNEC的董事，自2009年7月以来担任首席执行官。Raykov从2006年1月到2007年12月担任Alchem Investment Partners and John Levin&Co.投资组合经理。在创立Alchem之前，Raykov先生是John A.Levin&Co.的投资组合经理和证券分析师。2002-2005年活动驱动基金。在加入John A.Levin&Co.之前，Raykov先生是Tiedemann Investment Group合并基金的证券分析师（1999-2002）和Bear Stearns的投资银行分析师（1998-1999）。Raykov先生在北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）获得工商管理学士学位。由于这些和其他专业经验，随着公司在药物开发行业的发展，Raykov先生在公司拥有财务专业知识和经验，因此能够为我们提供独特的见解和指导。
Rostislav Raykov has served as a director and as Chief Executive Officer of Fennec since July 2009. From January 2006 to December 2007 Mr. Raykov was a portfolio manager for Alchem Investment Partners. Prior to founding Alchem, Mr. Raykov was a portfolio manager and securities analyst for John A. Levin & Co. Event Driven Fund 2002-2005. Prior to joining John A. Levin & Co., Mr. Raykov was a securities analyst for the Merger Fund at Tiedemann Investment Group (1999-2002) and an investment banking analyst at Bear Stearns (1998-1999). Mr. Raykov earned a B.S. in Business Administration from the University of North Carolina at Chapel Hill.- Rostislav Raykov自2009年7月以来担任FENNEC的董事，自2009年7月以来担任首席执行官。Raykov从2006年1月到2007年12月担任Alchem Investment Partners and John Levin&Co.投资组合经理。在创立Alchem之前，Raykov先生是John A.Levin&Co.的投资组合经理和证券分析师。2002-2005年活动驱动基金。在加入John A.Levin&Co.之前，Raykov先生是Tiedemann Investment Group合并基金的证券分析师（1999-2002）和Bear Stearns的投资银行分析师（1998-1999）。Raykov先生在北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）获得工商管理学士学位。由于这些和其他专业经验，随着公司在药物开发行业的发展，Raykov先生在公司拥有财务专业知识和经验，因此能够为我们提供独特的见解和指导。
- Rostislav Raykov has served as a director and as Chief Executive Officer of Fennec since July 2009. From January 2006 to December 2007 Mr. Raykov was a portfolio manager for Alchem Investment Partners. Prior to founding Alchem, Mr. Raykov was a portfolio manager and securities analyst for John A. Levin & Co. Event Driven Fund 2002-2005. Prior to joining John A. Levin & Co., Mr. Raykov was a securities analyst for the Merger Fund at Tiedemann Investment Group (1999-2002) and an investment banking analyst at Bear Stearns (1998-1999). Mr. Raykov earned a B.S. in Business Administration from the University of North Carolina at Chapel Hill.